Changeflow GovPing Healthcare & Life Sciences Vigil Neuroscience TREM2 Agonists ATP Transport...
Routine Rule Added Final

Vigil Neuroscience TREM2 Agonists ATP Transporter 1 Patent EP4255567A1

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4255567A1 for Vigil Neuroscience, Inc., covering TREM2 agonists for the treatment of diseases related to ATP-binding cassette transporter 1 dysfunction. The patent names inventors Papapetropoulos, Fisher, and Brennan, with applications extending to neurological conditions including Alzheimer's and Parkinson's diseases. The patent designates 35 Contracting States for protection.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.

What changed

The EPO published patent application EP4255567A1 for Vigil Neuroscience, Inc., covering TREM2 agonist compositions and methods of treating diseases related to ATP-binding cassette transporter 1 dysfunction. The patent application, with inventors Papapetropoulos, Fisher, and Brennan, includes multiple IPC classifications covering neurological applications such as Alzheimer's and Parkinson's diseases, as well as metabolic conditions.\n\nThis patent publication affects biotechnology and pharmaceutical companies engaged in TREM2-targeted therapeutic development or ATP-binding cassette transporter research. Companies operating in this space should review their R&D programs for potential licensing needs or freedom-to-operate analysis regarding TREM2 agonist technologies.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS

Publication EP4255567A1 Kind: A1 Apr 15, 2026

Applicants

Vigil Neuroscience, Inc.

Inventors

PAPAPETROPOULOS, Spyridon, FISHER, Richard, BRENNAN, Matthew

IPC Classifications

A61P 25/00 20060101AFI20241011BHEP A61P 25/14 20060101ALI20241011BHEP A61P 25/28 20060101ALI20241011BHEP A61K 48/00 20060101ALI20241011BHEP C07K 14/705 20060101ALI20241011BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4255567A1

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies Research institutions
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Patent grant TREM2 agonist therapeutics ATP transporter dysfunction treatment
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!